Latest News
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Pemetrexed and Platinum Chemotherapy as First-Line Treatment for Adult Patients With Unresectable Advanced or Metastatic MPM
Details >FDA Approves Novartis' Kisqali® (ribociclib) in Combination With an Aromatase Inhibitor (AI) to Reduce Risk of Recurrence in People With HR+/HER2- Early Breast Cancer
Details >Report Broken Links
Have you encountered a problem with a URL (link) on this page not working or displaying an error message? Help us fix it!